[go: up one dir, main page]

NO20043158L - Substituerte kinazolinderivater som inhibitorer av aurorakinaser - Google Patents

Substituerte kinazolinderivater som inhibitorer av aurorakinaser

Info

Publication number
NO20043158L
NO20043158L NO20043158A NO20043158A NO20043158L NO 20043158 L NO20043158 L NO 20043158L NO 20043158 A NO20043158 A NO 20043158A NO 20043158 A NO20043158 A NO 20043158A NO 20043158 L NO20043158 L NO 20043158L
Authority
NO
Norway
Prior art keywords
aurorakinases
inhibitors
quinazoline derivatives
substituted quinazoline
substituted
Prior art date
Application number
NO20043158A
Other languages
English (en)
Other versions
NO328159B1 (no
Inventor
Frederic Henri Jung
Georges Rene Pasquet
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20043158L publication Critical patent/NO20043158L/no
Publication of NO328159B1 publication Critical patent/NO328159B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20043158A 2001-12-24 2004-07-23 Substituerte kinazolinderivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater inneholdende slike samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom. NO328159B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403357 2001-12-24
PCT/GB2002/005845 WO2003055491A1 (en) 2001-12-24 2002-12-20 Substituted quinazoline derivatives as inhibitors of aurora kinases

Publications (2)

Publication Number Publication Date
NO20043158L true NO20043158L (no) 2004-09-16
NO328159B1 NO328159B1 (no) 2009-12-21

Family

ID=8183051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043158A NO328159B1 (no) 2001-12-24 2004-07-23 Substituerte kinazolinderivater, fremgangsmate for fremstilling av slike, farmasoytiske preparater inneholdende slike samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom.

Country Status (31)

Country Link
US (2) US7402585B2 (no)
EP (1) EP1463506B1 (no)
JP (1) JP4498741B2 (no)
KR (1) KR101029281B1 (no)
CN (1) CN100491372C (no)
AR (1) AR038052A1 (no)
AT (1) ATE446093T1 (no)
AU (1) AU2002353196B2 (no)
BR (1) BRPI0215312B8 (no)
CA (1) CA2471577C (no)
CY (1) CY1109681T1 (no)
DE (1) DE60234125D1 (no)
DK (1) DK1463506T3 (no)
ES (1) ES2333702T3 (no)
HU (1) HU229477B1 (no)
IL (1) IL162541A0 (no)
IS (1) IS2758B (no)
MX (1) MXPA04006260A (no)
MY (1) MY141739A (no)
NO (1) NO328159B1 (no)
NZ (1) NZ533440A (no)
PL (1) PL211694B1 (no)
PT (1) PT1463506E (no)
RU (1) RU2323215C2 (no)
SA (1) SA03230531B1 (no)
SI (1) SI1463506T1 (no)
TW (1) TWI335818B (no)
UA (1) UA82058C2 (no)
UY (1) UY27604A1 (no)
WO (1) WO2003055491A1 (no)
ZA (1) ZA200404923B (no)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
MXPA04006260A (es) * 2001-12-24 2005-03-31 Astrazeneca Ab Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
EP1578755B1 (en) 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
BRPI0409427A (pt) 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
CA2531142A1 (en) * 2003-07-03 2005-01-13 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
WO2005016346A1 (en) * 2003-08-14 2005-02-24 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
CA2542076C (en) 2003-10-14 2013-02-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
SG156650A1 (en) 2004-07-16 2009-11-26 Sunesis Pharmaceuticals Inc Thienopyrimidines useful as aurora kinase inhibitors
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
CA2581516C (en) 2004-10-12 2013-06-11 Astrazeneca Ab Quinazoline derivatives
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
EP1876178B1 (en) 2005-04-28 2015-05-27 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
CA2615946A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
NZ567241A (en) * 2005-09-30 2010-08-27 Miikana Therapeutics Inc Substituted pyrazole compounds
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
US7560551B2 (en) 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
ES2502790T3 (es) 2006-01-23 2014-10-06 Amgen Inc. Moduladores de la cinasa Aurora y método de uso
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
JP2009528336A (ja) * 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キノリン誘導体
MX2008011769A (es) * 2006-03-20 2008-09-25 Hoffmann La Roche Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
WO2007107469A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
US20070287706A1 (en) * 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
CA2664356A1 (en) 2006-10-05 2008-04-10 Banyu Pharmaceutical Co., Ltd. Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP2137177B1 (en) 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
US20090029992A1 (en) * 2007-06-11 2009-01-29 Agoston Gregory E Substituted pyrazole compounds
CN101743242A (zh) 2007-06-29 2010-06-16 苏尼西斯制药有限公司 用作raf激酶抑制剂的杂环化合物
EP2262796A1 (en) 2008-03-04 2010-12-22 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
EP2288611B1 (en) 2008-03-20 2013-05-15 Amgen Inc. Aurora kinase modulators and method of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
PL2396307T3 (pl) * 2009-02-11 2015-03-31 Merck Patent Gmbh Nowe aminowe azaheterocykliczne karboksyamidy
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
EP2465842A1 (de) * 2010-12-17 2012-06-20 Sika Technology AG Amine mit sekundären aliphatischen Aminogruppen
SG192769A1 (en) 2011-03-04 2013-09-30 Glaxosmithkline Ip No 2 Ltd Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
WO2013143466A1 (zh) * 2012-03-27 2013-10-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TWI630203B (zh) * 2013-02-21 2018-07-21 葛蘭素史克智慧財產發展有限公司 做為激酶抑制劑的喹唑啉類
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
PE20160930A1 (es) 2013-09-16 2016-09-03 Astrazeneca Ab Nanoparticulas polimericas terapeuticas y metodos para su elaboracion y uso.
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
JP6527513B2 (ja) 2013-11-20 2019-06-05 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのキナゾリン誘導体
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
SMT202100115T1 (it) 2014-03-26 2021-05-07 Astex Therapeutics Ltd Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
AU2015238305B2 (en) 2014-03-26 2020-06-18 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
EA032473B1 (ru) 2014-12-23 2019-05-31 Аксикин Фармасьютикалз, Инк. 3,5-диаминопиразоловые ингибиторы киназы
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2017050864A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv New compounds
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (no) 1994-11-12 1997-12-01 Zeneca Ltd
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DE69925141T2 (de) * 1998-10-08 2006-04-27 Astrazeneca Ab Chinazolin derivate
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
PL354323A1 (en) * 1999-09-21 2004-01-12 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB0006864D0 (en) * 2000-03-21 2000-05-10 Smithkline Beecham Plc New use
ES2305081T3 (es) 2000-06-28 2008-11-01 Astrazeneca Ab Derivados de quinozolina sustituidos y su uso como inhibidores.
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
MXPA04006260A (es) * 2001-12-24 2005-03-31 Astrazeneca Ab Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
US7105425B1 (en) * 2002-05-16 2006-09-12 Advanced Micro Devices, Inc. Single electron devices formed by laser thermal annealing
EP1578755B1 (en) * 2002-12-24 2007-08-22 AstraZeneca AB Phosphonooxy quinazoline derivatives and their pharmaceutical use
BRPI0409427A (pt) * 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
ES2308182T3 (es) * 2003-06-02 2008-12-01 Astrazeneca Ab Derivadosde (3-((quinazolin-4-il)amino)-1h-pirazol-1-il)acetamida y compuestos relacionados como inhibidores de quinasas aurora para el tratamiento de enfermedades proliferativas tales como el cancer.
JP2008515961A (ja) * 2004-10-12 2008-05-15 アストラゼネカ アクチボラグ 癌に対する使用のためのキナゾリン誘導体
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
EP1888572A1 (en) * 2005-05-28 2008-02-20 AstraZeneca AB Quinazolines and their use as aurora kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
GB0609617D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
EP2231281A2 (en) * 2007-12-12 2010-09-29 AstraZeneca AB Combination comprising a mek inhibitor and an aurora kinase inhibitor

Also Published As

Publication number Publication date
KR101029281B1 (ko) 2011-04-18
CN100491372C (zh) 2009-05-27
IL162541A0 (en) 2005-11-20
CY1109681T1 (el) 2014-08-13
IS7328A (is) 2004-06-21
NZ533440A (en) 2006-08-31
ES2333702T3 (es) 2010-02-26
ATE446093T1 (de) 2009-11-15
AR038052A1 (es) 2004-12-22
TW200410697A (en) 2004-07-01
CN1620296A (zh) 2005-05-25
PL371253A1 (en) 2005-06-13
TWI335818B (en) 2011-01-11
CA2471577A1 (en) 2003-07-10
BR0215312A (pt) 2004-12-07
MXPA04006260A (es) 2005-03-31
AU2002353196A1 (en) 2003-07-15
MY141739A (en) 2010-06-15
IS2758B (is) 2011-10-15
UA82058C2 (uk) 2008-03-11
PL211694B1 (pl) 2012-06-29
AU2002353196B2 (en) 2008-01-17
SA03230531B1 (ar) 2008-09-08
HU229477B1 (en) 2014-01-28
HUP0402454A2 (hu) 2005-03-29
WO2003055491A1 (en) 2003-07-10
US20090215770A1 (en) 2009-08-27
PT1463506E (pt) 2009-12-10
RU2323215C2 (ru) 2008-04-27
KR20040066929A (ko) 2004-07-27
RU2004122926A (ru) 2005-07-10
ZA200404923B (en) 2005-11-30
DE60234125D1 (de) 2009-12-03
CA2471577C (en) 2011-08-02
US7402585B2 (en) 2008-07-22
SI1463506T1 (sl) 2010-01-29
EP1463506A1 (en) 2004-10-06
JP4498741B2 (ja) 2010-07-07
EP1463506B1 (en) 2009-10-21
US20050070561A1 (en) 2005-03-31
HUP0402454A3 (en) 2009-08-28
UY27604A1 (es) 2003-07-31
BRPI0215312B8 (pt) 2021-05-25
HK1076598A1 (zh) 2006-01-20
BRPI0215312B1 (pt) 2018-03-27
NO328159B1 (no) 2009-12-21
SA03230531A (ar) 2005-12-03
DK1463506T3 (da) 2010-01-11
JP2005525307A (ja) 2005-08-25

Similar Documents

Publication Publication Date Title
NO20043158L (no) Substituerte kinazolinderivater som inhibitorer av aurorakinaser
NO20050636L (no) Inhibitorer av tyrosinkinaser
NO20033399D0 (no) Eterderivater anvendelige som inhibitorer av PDE4-isoenzymer
NO20033593D0 (no) Kinazoliner som MMP-13 inhibitorer
DK1667991T3 (da) Quinazolinderivater som tyrosinkinaseinhibitorer
DK1650203T3 (da) Quinolinonderivater som tyrosinkinaseinhibitorer
SE0701538L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
NO20043726L (no) Heteroarylforbindelser anvendelige som inhibitorer av GSK-3
NO20022139L (no) Kinazolinderivater som VEGF inhibitorer
DK1438306T3 (da) Derivater af UK-2A
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20026010L (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
EE200300459A (et) Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena
DK1556375T3 (da) Flavonderivater som inhibitorer af cyklinafhængige kinaser
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
DK1178986T3 (da) Furanonderivater som inhibitorer af cathepsin S
NO20050563L (no) N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon
NO20021959D0 (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20041968L (no) Anvendelse av cystationin
DK1562955T3 (da) Quinazolinderivater som Src-tyrosinkinaseinhibitorer
NO20041938L (no) Anvendelse av fosfodiesterase IV-inhibitorer
NO20035206L (no) Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
NO20030820L (no) Anvendelse av vitamin D derivater som benresorpsjons inhibitorer

Legal Events

Date Code Title Description
MK1K Patent expired